Instil Bio
Dr. Gibson, PhD, is an experienced drug developer, having contributed to the successful approval of multiple blockbuster oncology therapeutics, including temozolomide, erlotinib, crizotinib, and sorafenib. Dr. Gibson is currently the CEO of Adanate, an immunotherapy company. Previously, Dr. Gibson has held Chief Scientific Officer roles in multiple pharma and biotech companies, including Regulus Therapeutics, Pfizer Oncology, and OSI Pharmaceuticals. At Pfizer he was a member of the global R&D leadership team as well as a member of the Oncology Business unit leadership team. He has also held numerous academic appointments, including Associate Professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. Dr. Gibson earned his PhD from the University of Aston, Birmingham, England.
This person is not in the org chart
This person is not in any offices
Instil Bio
1 followers
Instil Bio is a cell therapy company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers. TIL are a patient’s own T cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. The company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered TIL. The company is led by world-class cell therapy experts and backed by premier global institutional investors. Instil is located in the greater Los Angeles area with additional manufacturing and research facilities in Manchester, UK.